Search clinical trials for: HNSCC treatment

Total 63150 results

LG Chem

Not yet recruiting

Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (LB-LR1109)

Urothelial Carcinoma | Malignant Melanoma | Non-small Cell Lung Cancer(NSCLC) | Head and Neck Squamous Cell Carcinoma(HNSCC) | Renal Cell Carcinoma(RCC)
Lund University Hospital

Recruiting

a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients (ARTSCAN VI)

Head and Neck Squamous Cell Carcinoma

Sweden
Grit Biotechnology

Not yet recruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma

HNSCC | Adults

China
Beijing Tongren Hospital

Recruiting

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy | Pembrolizumab

China
GlaxoSmithKline
iTeos Therapeutics

Recruiting

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Neoplasms, Head and Neck

United States, Italy, Spain, Taiwan, Germany, Greece, Korea, Republic of, Romania, Sweden, Turkey, Canada, Argentina, Finland, Brazil, Japan, Poland, Portugal, France, Denmark, Hungary, Norway
Guy's and St Thomas' NHS Foundation Trust
King's College London

Not yet recruiting

Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET

Cancer | Diagnosis | Resistant Cancer | Response, Acute Phase
Sichuan Cancer Hospital and Research Institute

Recruiting

The Effect of Nitozumab in the Treatment of Head and Neck Squamous Cell Carcinoma

HNSCC

China
European Organisation for Research and Treatment...
Merck Sharp & Dohme LLC; Swiss Group for Clinical Cancer Research

Not yet recruiting

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer (PROLoNg)

Oligometastatic Squamous Cell Carcinoma of the Head and Neck
Kyunghee Burkitt, DO, PhD

Not yet recruiting

Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC (HPV)

Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | HPV-Related Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the Hypopharynx

United States
Bayer

Recruiting

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Canada, Singapore, United Kingdom, Belgium
University of Chicago

Recruiting

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Head and Neck Cancer Stage IV | Head and Neck Cancers - Throat

United States
Florida International University

Recruiting

Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom

ADHD

United States
Zhejiang Provincial People's Hospital

Recruiting

Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC

Head and Neck Squamous Cell Carcinoma

China
Xijing Hospital

Not yet recruiting

Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC

Head and Neck Squamous Cell Carcinoma
Fifth Affiliated Hospital, Sun Yat-Sen University
Dongguan People's Hospital

Recruiting

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Treatment

China
Charite University, Berlin, Germany
Helmholtz-Zentrum Dresden-Rossendorf; Max-Delbrück-Centrum Berlin

Recruiting

Artificial Intelligence in Functional Imaging for Individualized Treatment of Head and Neck Squamous Cell Carcinoma Patients (KIVAL-KHT)

HNSCC

Germany
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

China
Savana Research
Head and Neck Cancer International Group (HNCIG)

Recruiting

Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence. HNC-TACTIC. (HNC-TACTIC)

Head and Neck Cancer

Spain
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

China
Alpha Tau Medical LTD.

Recruiting

A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC

Skin Cancer | Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

Israel
Kura Oncology, Inc.

Recruiting

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

HNSCC

United States
Nanobiotix

Recruiting

NBTXR3 With or Without Cetuximab in LA-HNSCC

Aged | Locally Advanced Head and Neck Squamous Cell Carcinoma

France, Spain, Israel, United States, Taiwan, Finland, Japan, Belgium, Korea, Republic of, Hungary, China, Georgia, Portugal, Austria, Bulgaria, Canada, Czechia, Germany, Greece, Romania, Serbia
The First Affiliated Hospital of Soochow University
Biotech Pharmaceutical Co., Ltd.; Cinda Biopharmaceutical (Suzhou) Co., Ltd.

Not yet recruiting

Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC. (Carpp-1)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer

China
Gruppo Oncologico del Nord-Ovest

Recruiting

Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC (PRIME)

Head and Neck Squamous Cell Carcinoma

Italy
Alpha Tau Medical LTD.

Recruiting

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia

Skin Cancer | Mucosal Neoplasm of Oral Cavity | Soft Tissue Neoplasm

Israel
Icahn School of Medicine at Mount Sinai

Recruiting

Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Hookipa Biotech GmbH

Recruiting

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

HPV-Related Squamous Cell Carcinoma

United States, Spain, Netherlands
Jason J. Luke, MD

Recruiting

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Melanoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | Cholangiocarcinoma | Bladder Cancer | Renal Cancer | Anal Cancer | Merkel Cell Carcinoma | HNSCC

United States
Brigham and Women's Hospital
National Cancer Institute (NCI); Dana-Farber Cancer Institute; University of... and other collaborators

Recruiting

A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation (Potlako+)

Neoplasms | Cervical Cancer | Breast Cancer | Hiv | Vulvar Cancer | Anal Cancer | HNSCC | Cancer Suspect

Botswana
Robert L. Ferris, MD, PhD
Bristol-Myers Squibb

Recruiting

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Regeneron Pharmaceuticals
Sanofi

Recruiting

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States
Alpha Tau Medical LTD.

Recruiting

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.

Skin Cancer | Mucosal Neoplasm of Oral Cavity | Soft Tissue Neoplasm

Israel
Alpha Tau Medical LTD.

Recruiting

Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)

Skin Cancer | Mucosal Neoplasm of Oral Cavity | Soft Tissue Neoplasm

Italy
Zhejiang Cancer Hospital

Recruiting

A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC

Head and Neck Neoplasms

China
Seagen Inc.
Merck Sharp & Dohme LLC; Genmab

Recruiting

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (innovaTV 207)

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Exocrine Pancreatic Cancer | Carcinoma, Squamous Cell of Head and Neck

United States, Canada, France, Germany, Italy, Spain, United Kingdom, Puerto Rico
Groupe Oncologie Radiotherapie Tete et Cou
National Cancer Institute, France

Recruiting

Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) (SANTAL)

HNSCC

France
Astex Pharmaceuticals, Inc.

Active, not recruiting

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Lymphoma | Solid Tumors

United States, Belgium, Spain, Hungary, Italy, Canada, United Kingdom, France
Seagen Inc.
Merck Sharp & Dohme LLC

Terminated

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Melanoma | Small Cell Lung Cancer | Prostate Cancer | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma | Non-small Cell Lung Cancer, Squamous | Non-small Cell Lung Cancer, Non-squamous

United States, Korea, Republic of, Italy, United Kingdom, Australia, Taiwan
Bayer

Active, not recruiting

A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

Advanced Solid Tumors

United States, Singapore, Italy, United Kingdom
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

Squamous Cell Carcinoma of Head and Neck

Spain, Italy, United States, Chile, France, Argentina, Canada, Germany, Korea, Republic of, Netherlands, Taiwan
University of Colorado, Denver
Cancer League of Colorado

Completed

Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC

HNSCC

United States
Alpha Tau Medical LTD.

Active, not recruiting

Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)

Skin Cancer | Mucosal Neoplasm of Oral Cavity | Soft Tissue Neoplasm

Israel
The Netherlands Cancer Institute

Completed

ctDNA as a Biomarker for Treatment Response in HNSCC (PECAN)

Carcinoma, Squamous Cell of Head and Neck

Netherlands
POINT Biopharma

Active, not recruiting

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Soft Tissue Sarcoma | Colorectal Cancer | Esophageal Cancer | Cholangiocarcinoma | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Melanoma (Skin)

United States, Canada
Merck Sharp & Dohme LLC

Completed

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Austria, Brazil, France, Israel, Korea, Republic of, Norway, Spain, United Kingdom
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair Deficiency

United States
Lawson Health Research Institute

Active, not recruiting

A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719

Head and Neck Squamous Cell Cancer

Canada

Search clinical trials for: HNSCC treatment

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations